Paper Details

  1. Home
  2. Paper Details

Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.

Author: CaraballoRoberto H, EspecheAlberto, FasuloLorena, GalichioSantiago, PociechaJuan, ReyesGabriela, SemprinoMarcos

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

A retrospective study of 34 patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP) other than Lennox-Gastaut syndrome (LGS) showed that rufinamide as add-on therapy resulted in a greater than 50% decrease in seizures in 64.5% of patients and seizure freedom in 5.8%. Adverse effects were observed in 26.4% of patients. Rufinamide may be a viable treatment option in DEE and REP other than LGS.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Here, we present a multicenter series of patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP) other than Lennox-Gastaut syndrome (LGS) who were treated with rufinamide as add-on therapy. METHODS: Medical records of 34 patients with D...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.yebeh.2020.107074

データ提供：米国国立医学図書館（NLM）

Rufinamide: A Potential Oasis in the Desert of Epileptic Encephalopathies

Epileptic encephalopathies are severe neurological disorders characterized by frequent seizures and cognitive impairments. This study explores the potential of rufinamide, an antiepileptic drug, as an add-on therapy for children with various forms of epileptic encephalopathies other than Lennox-Gastaut syndrome (LGS). The authors retrospectively analyzed the medical records of 34 children who received rufinamide as an add-on treatment, finding that it significantly reduced seizure frequency in a majority of patients. This research offers a glimmer of hope for children with these challenging conditions.

A Promising Treatment: Rufinamide for Epileptic Encephalopathies

The study's findings suggest that rufinamide may be a valuable treatment option for children with epileptic encephalopathies other than LGS. It's like finding a refreshing oasis in the vast desert of neurological disorders, offering a potential pathway to improved seizure control and quality of life. However, it's important to note that rufinamide may not be effective for all children, and further research is needed to fully understand its long-term effects.

Navigating the Desert of Epilepsy: A Search for Solutions

Living with epilepsy, particularly in its more severe forms, can be a challenging journey. This study reminds us that there is ongoing research seeking new and improved treatments. It's like exploring a vast desert, searching for solutions and hope for those struggling with this complex condition. Consulting with a healthcare professional is essential to determine the best treatment options for your specific needs.

Dr.Camel's Conclusion

This research offers a glimmer of hope for children with epileptic encephalopathies. It's like finding a hidden oasis in the desert of neurological disorders, offering a potential pathway to improved seizure control and quality of life. While more research is needed, this study provides valuable insights into the potential of rufinamide as a therapeutic option for these challenging conditions.

Date :
  1. Date Completed 2021-02-01
  2. Date Revised 2021-02-01
Further Info :

Pubmed ID

32334364

DOI: Digital Object Identifier

10.1016/j.yebeh.2020.107074

Related Literature

Article Analysis
・Effects of rufinamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.